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This study shows that inMexico, a country at an advanced stage in the epidemiologic transition, with the national burden of disease
dominated by noncommunicable diseases, elevated blood pressure is a major clinical and public health problem. 31.7% of the Mex-
ican individuals aged 50 and over had systolic hypertension, and 47.3% were at systolic prehypertensive levels. Also, approximately
half of all cardiovascular deaths that occurred annually in the population ofMexico aged ≥50 years are attributable to above optimal
levels of systolic blood pressure. We think these estimates may help order health priorities in Mexico (and other middle-income
countries) at a time when the costs of medical care take a considerable share of the gross national product in most countries.
1. Introduction
Among middle-age and old-age adults, blood pressure (BP)
is strongly and directly associated with mortality in the
absence of a clear threshold until at least 115/75mmHg [1].
Not surprisingly, high BP is the most important cause of
stroke and one of themost important risk factors for coronary
heart disease (CHD) [1–3]. In fact, randomized controlled
trials have confirmed that treatment of hypertension reduces
the risk of cardiovascular disease (CVD) events at all ages
[4, 5]. Additionally, a recent meta-analysis has shown that the
risk of stroke is significantly reduced with antihypertensive
therapy in cohorts with prehypertensive baseline BP levels [6]
and, further, that lifestyle modifications also play a significant
role in reducing the risk of cardiovascular events among
prehypertensive patients [7].
HighBP andCVDaremajor causes of death anddisability
worldwide [8–11]. Although safe and effective strategies for
the prevention and control of high BP have been widely
available in many countries for over 50 years, overall BP
control rates remain suboptimal in most countries [12–17].
Mexico is a country at an advanced stage in the epidemiologic
transition with the burden of disease at the national level
dominated by noncommunicable diseases and related risk
factors, including very high rates of heart disease, stroke,
and hypertension [18]. In fact, CHD and stroke are the
second and third single leading causes of death in Mexico
[19]. Surprisingly, these excessive rates of noncommunica-
ble diseases, mostly CVD-related, exist in the context of
significant progress regarding the universal health coverage
system [20]. Although recent work has reported data on
the prevalence and control of hypertension in Mexico [21,
22], no information on the current burden of cardiovascular
mortality attributable to relevant past levels of hypertension
and prehypertension has been reported. This information
would inform public health authorities about the real impact
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of elevated BP on the main causes of death at the population
level.
Thus, this study estimates the current burden of CVD
mortality attributable to past levels of higher-than-optimal
systolic BP (SBP) in the Mexican population, specifically
among people 50 years and over, where SBP is the main
predictor of CVD risk and most CVD deaths are expected
to occur [1, 2]. In particular, we have taken into account a
reasonable time lag of at least a few years from exposure to
ensuingmortality burden [1, 23, 24]. In addition to informing
public policy in this country, this evidence could provide
valuable information to other low- andmiddle-income coun-
tries also experimenting epidemiological transition, where
burden of BP-related disease does not seem to be a public
health priority yet.
2. Methods
2.1. Survey Design. Our study is based on the 2005-2006
Mexican National Health and Nutrition Survey, a cross-
sectional study that collected data from a sample representa-
tive of theMexican population and that was conducted by the
MexicanNational Institute of Public Health betweenOctober
2005 and May 2006. Detailed methods of the study are
described elsewhere [25]. In brief, a probabilistic multistage
stratified cluster sampling method was used to select 48,600
households in all 32 states of Mexico, of which 47,152 agreed
to participate. The sampling process comprised the follow-
ing steps: (1) random selection of “Areas Geoestadı´sticas
Ba´sicas” (Basic Geostatistical Areas) or AGEB in each of
the 32 states with probability proportional to the number of
households; (2) selection of AGEB by county with probability
proportional to the county’s population; (3) selection of six
blocks per AGEB with equal probability; (4) selection of six
households per blockwith equal probability; and (5) selection
of one individual from each age group (a child, an adolescent,
and an adult aged ≥20 years) chosen with equal proba-
bility. The survey has power to make distinctions between
urban (≥2,500 inhabitants) and rural (<2,500 inhabitants)
areas. Sample weights for each participant were calculated
in order to adjust for the complex survey design based on
the corresponding age and gender distributions as well as
on national census information. All study participants gave
written informed consent. The study was approved by the
Research, Ethics, and Biosecurity committees of the Mexican
National Institute of Public Health.
2.2. Measurements. Data collection consisted of two home
visits by trained health personnel. During the first visit the
health interview and anthropometric measurements were
obtained, whereas during the second visit blood samples and
BP measurement were collected. A structured questionnaire
was administered to obtain sociodemographic and personal
health data including self-reports of previously diagnosed
type 2 diabetes, hypercholesterolemia, tobacco use, alcohol
consumption, physical activity, and history of cardiovascular
disease.
Anthropometric measures included weight, height, and
waist circumference, under standardized conditions. Height
was measured to the nearest 0.1 cm using a stadiometer with
an error of 5mm, whereas body weight was measured using
a digital scale with an error of 0.1 kg. Body mass index
(BMI) was calculated as weight (kg)/height (m2); obesity was
defined as a BMI ≥ 30 kg/m2 [26] and abdominal obesity as
waist circumference >90 cm in men and >80 cm in women.
Blood pressure was measured twice, using the dominant
arm of seated participants after resting for a minimum of 5
minutes. Calibrated standard mercury sphygmomanometers
were used and standardized methods and conditions were
followed [27]. The mean of the two BP readings was used
for analyses. For this study’s purpose, we defined systolic
hypertension as SBP ≥ 140mmHg, regardless of DBP values
or treatment status, and higher-than-optimal SBP as SBP ≥
120mmHg, and SBP categories followed classification from
international and national guidelines [28–31].
2.3. Statistical Analysis. For this study, we focused on the
10,004 participants aged 50 years and over with complete
data of the total Mexican adults surveyed. Descriptive data
are presented as frequencies and percentages for qualitative
variables and as mean ± standard deviation for quantitative
variables. Differences in percentage of people between hyper-
tension and no hypertension groups were assessed using the
𝜒
2 test (or Fisher exact test where appropriate). Analyses
were performedwith the “SurveyData” procedures in STATA
v.11.1 (StataCorp. LP, College Station, 2010) to account for the
complex sampling design.
Population attributable fraction (PAF) of cardiovascular
mortality attributable to higher-than-optimal SBP was calcu-
lated for eachCVDconsidered (those forwhich evidence on a
causal relationship with high BP is available), each age group
(by decades) and SBP (𝑖) category, according to the classical
formula [32, 33]: PAF
𝑖
= 𝑃
𝑖
(RR
𝑖
− 1)/(1 + ∑𝑃
𝑖
[RR
𝑖
− 1]).
For the total of SBP categories we used the formula: PAF =
∑
𝑖
𝑃
𝑖
(RR
𝑖
− 1)/(1 + ∑𝑃
𝑖
[RR
𝑖
− 1]), where RR
𝑖
stands for
relative risk of death for CVD in each age group and SBP
level (with respect to the reference category <120mmHg) and
𝑃 stands for the prevalence of SBP in the study population
in each category “𝑖” and age group. RR data were drawn
from the Prospective Studies Collaboration, a meta-analysis
of 61 studies on BP and mortality, including data on 1
million subjects with no prior CVD recorded at baseline [1].
To approximate to the BP categories used in international
guidelines and local guidelines in Mexico [28–31], we used
the RRs at midpoint for each BP category reported in
the Prospective Studies Collaboration. Percentages of SBP
categories were drawn from the nationwide survey of Mexico
[25] for subjects ≥50 years without previous clinical CVD.
Finally, the number of cardiovascular deaths attributable
to each SBP category and within each age group were
calculated by multiplying the corresponding PAF by the
number of cardiovascular deaths registered in each age
group in the Mexican population ≥50 according to official
statistics [19].The followingmortality causes were considered
CVD deaths: CHD (codes I20–I25) (65,371 deaths), stroke
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(I60–69, G45) (29,520 deaths), and other cardiovascular dis-
eases (25,677 deaths) including heart failure (I50), hyper-
tensive disease (I10–I15), atherosclerosis (I70), sudden death
(I46.1), rheumatic heart disease (I05–I09), and pulmonary
embolism (I26) according to the International Classification
of Diseases system 10th revision [34].
3. Results
3.1. Sample Characteristics. 41.5% of subjects (4150) were
aged 50–59 years old; 30%, 60–69; 20%, 70–79; and 8.5%, 80–
89. Fifty-seven percent were women, 28.6% were smokers,
32.6% had obesity (57.3%, abdominal obesity), 15.1% had
diabetes, 28.4% were sedentary, and 8.8% reported having a
previous CVD event (Table 1).Mean SBP in the study subjects
was 132.3 ± 19.3mmHg, and its stratification by sex, age, and
clinical characteristics is shown in Table 1.
3.2. Distribution of Systolic Blood Pressure. Overall, 31.7% of
individuals had systolic hypertension (SBP ≥ 140mmHg),
for either being untreated or uncontrolled. Some 47.3% of
individuals were at systolic prehypertensive levels, because
theywere either hypertensivewith their SBP values controlled
or treatment na¨ıve prehypertensive.
The prevalence of systolic hypertension was significantly
higher in women, older age, and those with obesity, diabetes
or sedentariness than in their counterparts (Table 1), but it
was lower among those who were smokers. The percentage
of people within the 120–129mmHg range was generally
somewhat higher than that within 130–139mmHg, except
for those with obesity (BMI ≥ 30 kg/m2), sedentariness, or
diabetes where the opposite occurred (Table 1). Interestingly,
prehypertensive categorieswere generallymore frequent than
any of the hypertension categories, except for obesity and
diabetes again where grade 1 hypertension took over the first
place.
3.3. Percentage of Cardiovascular Mortality Attributable to
High Systolic Blood Pressure. As shown in Table 2, the preva-
lence of systolic hypertension increased, and the percentage
of systolic prehypertensive levels decreased with age until age
80 and then tended to level off. RRs for cardiovascular death
rose steeply with increasing levels of SBP, decreased with age,
and they were noticeably higher for stroke among individuals
under the age of 80 (Table 2).
39–58% of all CHD deaths, 39–75% of all stroke deaths,
and 35–59% of other CVD deaths occurred in the population
of Mexico aged 50 and over were calculated to be attributable
to higher-than-optimal levels of SBP (Table 2). PAFs gener-
ally decreased with age and were higher for stroke under age
80. Hypertension categories accounted for the highest part of
PAF for all age groups and CVD types.
The figure shows that whereas RRs increased with pro-
gressively higher levels of SBP, population attributable frac-
tions (or risks) increased up to grade 1 systolic hypertension
levels and then decreased (Figure 1).
Overall, 63.6% of all CVD deaths occurred in the popula-
tion of Mexico ≥50 years were attributable to above optimal
SBP, 73.9% of all CVD deaths in individuals 50–69 years and
52.6% in those 70–89 years (Figure 1). A much lower but not
negligible 7–10% of all these cardiovascular disease deaths
that occurred arise from individuals at SBP 120–139mmHg.
3.4. The Absolute Burden of High Systolic Blood Pressure
on Cardiovascular Mortality in the Population. A total of
57,896 cardiovascular deaths were attributable to high SBP.
This stands for almost half (48%) of all annual cardio-
vascular deaths that occurred in the Mexican population
≥50 years (47% and 54.7% of all CHD and stroke deaths,
resp.) (Table 3). A total of 30,706 of these related deaths
were coronary heart disease deaths, 16,161 stroke deaths,
and 11,029 deaths from other CVDs. The highest number
of related deaths came from hypertension grade 1 and 2
(48,339 or 83.4%), and fell on patients over 70 years (38,598
or 66.6%) (Table 3). Nevertheless, systolic prehypertension
(120–139mmHg) accounted for 16.5% of all related deaths
(9,557 deaths), and 33.3% of all related deaths came from
individuals aged 50–69 years (19,298 deaths) (Table 3).
4. Discussion
This is the first study carried out inMexico, based on popula-
tion data representative of the whole population of Mexico,
that presents information on the burden of cardiovascular
mortality related to elevated SBP in noninstitutionalized
people older than 49 years. This study shows that elevated
systolic blood pressure is a major public health problem
in Mexico. As many as 58,000 cardiovascular deaths in the
Mexican population aged 50 and over are attributable to
elevated SBP levels, about half of all CVD deaths occurred in
those people at present; from these, 8 in ten are due to systolic
hypertension and 2 due to systolic prehypertension.
As in a previous study performed in Spain [35], CHD
accounted for more BP-related cardiovascular mortality than
stroke. However, in bothMexico and Spain, stroke accounted
for a higher PAF and percentage of all related deaths. This
may be partly due to the relatively higher prevalence of
hypertension and prehypertension and poorer BP control in
theMexican population than othermore developed countries
[21, 36–38], as these characteristics are more strongly related
to stroke [39, 40].
One in 3 related deaths were premature deaths (occurring
before age of 70 years; mean life expectancy in Mexico was
about 75 [41]), amounting to almost 20,000 annual cardio-
vascular deaths. Estimates of the contribution of raised blood
pressure to premature mortality are essential for anticipating
how much benefit from prevention could be potentially
achieved, especially in economically developing countries,
where healthcare resources are scarce and BP-related burden
is considerable [9, 11, 42].
Most related deaths came from hypertension, however
about 15–20% of related mortality arises from the relatively
minority who fall within prehypertensive levels, even in
individuals under the age of 70 (data not shown). This is
partially consistent with theory from Rose [43] that the
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Figure 1: Percent mortality from all cardiovascular diseases attributable to higher-than-optimal systolic blood pressure in the population
of Mexico aged 50 and over in 2010. The curve represents the smoothed distribution of systolic blood pressure (SBP) in the 2005-2006
Mexican sample based on SBP categories. The risk line represents the internationally-based relative risk values of cardiovascular mortality
corresponding to each SBP category. The numbers at the heads of the bars indicate the percentages of all cardiovascular deaths occurred in
Mexico in 2010 attributable to each category of SBP, by age.
Table 3: Number and distribution of cardiovascular deaths attributable to above optimal systolic blood pressure (SBP), by age and SBP
category in the population of Mexico aged 50 and over in 2010.
Coronary heart disease
𝑛 (%)
Stroke
𝑛 (%)
Other CVD
𝑛 (%)
All CVD
𝑛 (%)
Age (years)
50–59 3909 (12.7) 2091 (12.9) 1284 (11.6) 7284 (12.6)
60–69 6483 (21.1) 3370 (20.8) 2161 (19.6) 12014 (20.7)
70–79 8470 (27.6) 5430 (33.6) 2917 (26.4) 16817 (29.0)
80–89 11844 (38.6) 5270 (32.6) 4667 (42.3) 21781 (37.6)
SBP (mmHg)
120–129 1993 (6.5) 890 (5.5) 589 (5.3) 3472 (6.0)
130–139 3317 (10.8) 1500 (9.3) 1268 (11.5) 6085 (10.5)
140–159 10620 (34.6) 5374 (33.2) 3935 (35.7) 19929 (34.4)
160–179 8694 (28.3) 4771 (29.5) 3121 (28.3) 16586 (28.6)
≥180 6082 (19.8) 3626 (22.4) 2116 (19.2) 11824 (20.4)
Total
Number 30706 (100) 16161 (100) 11029 (100) 57896 (100)
% of total CVD 47.0 54.7 42.9 48.0
Total: sum of related deaths over all age groups or all SBP categories, for each cardiovascular disease (CVD) type and for all CVD together. % of total CVD:
percentage of all cardiovascular deaths registered in the population of Mexico over 50 that were attributable to higher-than-optimal blood pressure (SBP ≥
120mmHg).Other cardiovascular disease: heart failure, hypertensive disease, atherosclerosis, sudden death, rheumatic heart disease, and pulmonary embolism.
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graded increase of individual RR of CVDmortality through-
out the SBP range is not accompanied by a corresponding
increase in the population burden of mortality, since the
percentage of individuals decreases steeply above grade 1
systolic hypertension (see Figure 1).
4.1. Clinical and Public Health Implications. These findings
may have important implications since high SBP is a major
clinical and public health problem in Mexico. The huge bur-
den of hypertension-related cardiovascular mortality hints
at a worrying combination of high prevalence and poor
management of hypertension. In fact, one-third of adult
Mexicans are systolic-based hypertensive patients, who are
either untreated or uncontrolled despite treatment. Thus,
it is reasonable to suggest that a substantial portion of
deaths attributable to hypertension are likely to be due to
uncontrolled hypertension. Achieving higher levels of BP
control in this population would potentially reap significant
benefits in the formof important reductions in cardiovascular
mortality, thus demonstrating the large harmful impact that
hypertension has on the health of an entire population.
However, the figures of the clinical epidemiology of
hypertension management (awareness, treatment, and con-
trol) are persistently poor in many countries, especially in
less developed countries [36, 37]. This suggests that if a
substantial impact is to be achieved in the national figures of
cardiovascular burden in the population, better detection and
treatment of high blood pressure (rather than only hyperten-
sion) based on both lifestyle intervention and effective drug
prescription should be implemented [30, 44, 45]. In other
terms, no matter how big the problem of hypertension is,
the burden of cardiovascular mortality arises from the whole
range of BP values. Prevention, to be effective, must address
the whole range of the problem.
Finally, results from this study may inform related public
health policy in other middle-income countries also experi-
menting epidemiological transition.
4.2. Limitations and Strengths. Our results should be inter-
preted in the context of the study’s limitations. First, we
may have overestimated the prevalence of hypertension since
BP measures used for analyses were based on the average
of only two BP readings and given the known fact that
BP tends to fall spontaneously over time. Second, the input
RRs used to calculate the BP-related CVD mortality, mainly
coming from European and American studies, may probably
be slightly lower than those in Mexicans, especially those
referred to CHD [46]. This may have resulted in some
underestimation of related mortality. However, RRs for most
risk factors effects seem to be similar across populations [40,
47], indicating that combining and applying international
studies to Mexico is reasonably appropriate awaiting for a
more accurate estimation from local longitudinal studies.
Third, since noRRs for combined values of SBP andDBPwere
available from the Prospective Studies Collaboration [1], we
only used SBP. In our study, exclusion of elevated DBP may
have resulted in underestimation of relatedmortality. Fourth,
for calculating PAFwe used classical formulae [32, 33], whose
validity is maximized in the absence of confounding. To
reduce confounding, we controlled the effect of age, the
main confounder in the relationship between SBP and CVD
mortality, by using age-stratified RRs and BP prevalence.
Fifth, we calculated the current burden of CVD mortality
related to past exposure to elevated levels of SBP (related
burden), instead of the future burden due to current exposure
(avoidable burden). Nevertheless, related burden may be
interesting, because is likely to be a good predictor of
avoidable mortality [23]. To this purpose, we assumed a time
lag of about 5 years between exposure to high BP and current
mortality, which is obviously subjected to some uncertainty
since no clear lag periods have been established. Finally, we
have used mortality and no disability as an estimation of
burden of disease. Future studies could examine disability-
adjusted life years.
It should also be noted that mortality burden attributable
to high SBP should be interpreted in the context of other
CVD risk factors interacting with BP to produce this burden
of deaths; and that even if prevention were successful to
avoid disease, death will eventually be only postponed, this
nevertheless being worth achieving (healthier and longer
life).
Major strengths of this study include the size and char-
acteristics of the database analysed. The National Health
and Nutrition Survey of Mexico is larger than similar
surveys in most developed countries; it closely represents
the Mexican adult population, and it collects objective BP
measures. However women were slightly overrepresented in
the Mexican National Survey (58.7% versus 52.3% in the
general population), due in part to the reduced presence
of men in the household during working hours, the age,
and sex distribution of the sample which closely resembled
the general population (data not shown). Future research
will continue to benefit from the data provided from large
ongoing national surveys of the Mexican population which
enable the surveillance of the clinical epidemiology of hyper-
tension and prehypertension and the impact of BP-related
cardiovascular mortality.
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